智通财经APP获悉，兆科眼科-B(06622)高开近5%，截至发稿，涨4.72%，报1.33港元，成交额2.79万港元。
消息面上，兆科眼科发布公告，中国国家药品监督管理局已受理公司核心产品之一、用于治疗儿童近视加深的NVK002(低剂量阿托品0.01%)的简化新药申请。此项简化新药申请乃以其在中国的第III期临床试验结果为基础。
此外，兆科眼科近期公告，TAB014（公司核心候选药物之一）用于治疗湿性（新生血管）老年黄斑部病变（“wAMD”）第III期临床试验的积极顶线结果。该项临床试验成功达到主要终点及关键次要终点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.